Aptamer Group PLC

Aptamer Group PLC, along with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, the rest of Europe, the United States, and internationally. Its Optimer platform enables the discovery and development of optimized DNA and RNA aptamers that bind to target molecules. The platform is used in research reagents and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications, serving pharmaceutical, diagnostic, and bioprocessing companies. The company has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius, and was founded in 2008 with headquarters in York, the United Kingdom.